Three-Year Outcomes in Kidney Transplant Patients Randomized to Steroid-Free Immunosuppression or Steroid Withdrawal, with Enteric-Coated Mycophenolate Sodium and Cyclosporine: The Infinity Study

Table 1

Demographics and baseline characteristics.

	Without initial steroids (𝑛=70)	With initial steroids (𝑛=61)	𝑃 value
Recipients
Male gender, 𝑛 (%)	49 (70.0)	35 (57.4)	0.133
Age (years), mean ± SD	52.4±10.0	50.7±11.6	0.496
White race, 𝑛 (%)	65 (92.9)	56 (91.8)	0.120
Body mass index (kg/m^2), mean ± SD	24.9±3.7	25.9±4.7	0.080
Panel reactive antibodies 0%, 𝑛 (%)	69 (98.6)	61 (100.0)	1.000
Delayed graft function	8 (11.4)	13 (21.3)	0.124
Donors
Male gender, 𝑛 (%)	43 (61.4)	37 (60.7)	0.928
Age (years), mean ± SD	48.9 (15.4)	46.1 (15.7)	0.276
Deceased donor (heart beating), 𝑛 (%); Living unrelated, 𝑛 (%)	70 (100.0); 0	60 (98.4); 1 (1.6)	0.466
Transplant
Recipient <60 years, donor <60 years, 𝑛(%)	50 (71.4)	46 (75.4)	0.607
Recipient ≥60 years, donor ≥60 years, 𝑛 (%)	11 (15.7)	10 (16.4)	0.916
Cold ischemia time (hours), mean ± SD	17.5 (6.0)	16.9 (4.8)	0.937
CMV status, 𝑛 (%)
D+/R−	21 (30.0)	15 (24.6)	0.489
D+/R+	15 (21.4)	12 (19.7)	0.804
D−/R−	17 (24.3)	21 (34.4)	0.202
D−/R+	17 (24.3)	13 (21.3)	0.686

CMV: cytomegalovirus; SD: standard deviation.